看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' `% p+ Z9 v; s9 k# B5 W
( h3 r& s* Y+ d$ x
; |! D8 T- U7 }) M2 Y5 mCurrently available feasibility data for possible combination strategies. & ?8 p7 T9 B0 z5 m8 Q9 c# r: f
————————————————————————————————
# l# K1 A: x5 w( d, XCombination Feasibility according to preliminary data % ?! g7 x; g9 \: o- B/ z2 o* P4 U
——————————————————————————————————% K4 M9 ~, f+ P$ R; w3 d- h/ T
Bevacizumab + sorafenib Yes, reduced dose ; k5 b9 n0 w7 i9 [, }2 N- S, u
Bevacizumab + sunitinib† No
! l0 \5 y' t1 V8 @Bevacizumab + temsirolimus Yes
- g N) c2 i* fBevacizumab + everolimus Yes
) R3 S* S$ F5 s& Z% M& G% w: C2 MSorafenib + sunitinib ?
# k7 A6 w/ u6 \5 JSorafenib + temsirolimus Yes, reduced dose 6 M/ J+ Z' t, |9 T' K
Sorafenib + everolimus Yes, reduced dose / U k% F& D i/ O0 |' l6 ?
Sunitinib + temsirolimus† No 5 Q5 |) d1 o( ` s* M+ O
Sunitinib + everolimus ? ( T; J4 @- U% o- M2 X" g0 C
Temsirolimus + everolimus ? 5 A2 x' L1 b8 J& F. @& u) x$ L
————————————————————
3 |7 _; i& J) T8 g( _, `1 A†Led to US FDA warning.
) q$ N* I3 o7 K& N?: As yet unattempted combination.
, J6 E& j3 B: z9 t) o, f, T |